FDA Approves CRESTOR — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's CRESTOR (rosuvastatin calcium) for Cholesterol Management AstraZeneca Pharmaceuticals LP has received FDA approval for CRESTOR (rosuvastatin calcium), an oral statin therapy poised to compete in the lucrative cholesterol-management market against established players like Lipitor and Zocor. The approval positions AstraZeneca to capture significant market share in the multibillion-dollar statin category, which treats cardiovascular disease risk in millions of patients worldwide.